glp 1 agonisten GLP-1 Agonists: A Comprehensive Overview The role of GLP1 receptor

E.CharitosI

[93] found that in patients who had HF and a preserved LVEF, a notable increase in LVEF with a 1-week treatment of liraglutide

Dong Z, Feng L, Chao Y, Hao Y, Chen M, Gong F, et al

In 2023 the American Academy of Pediatrics (AAP) and other expert bodies began endorsing earlier consideration of pharmacotherapy: weight-loss medications are now recommended for youth aged 12 (and even younger in controlled settings) who have obesity or overweight with comorbidities, after insufficient response to intensive lifestyle therapy

Even if, in the first couple years of Mounjaro and Wegovy both being approved for the weight loss indication, the impact from just those taking it who can afford it/have the insurance for it can be significant